Jennifer S. Buell/LinkedIn
Jul 17, 2025, 01:09
Jennifer Buell: MiNK Therapeutics Featured in Frontiers – Immunology
Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post on X:
“MiNK Therapeutics featured Frontiers – Immunology, after:
- 2 Nature Oncogene Journal pubs
- Standout Ph2 data AACR -IO.
- Durable solid tumor responses
- No GvHD, No lymphodepletion, No HLA matching
- STTR grant to advance in GVHD
- Dual-function. Off-the-shelf. Ready to go.
More posts featuring MiNK Therapeutics.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54
Aug 8, 2025, 15:49